

New vaccine projects target African HIV strainsTwo innovative research projects launched in November aim to develop cheap, safe and effective AIDS vaccines targeted specifically at HIV virus strains most common in Africa.These initiatives — a UK-Kenyan partnership and a US-South African collaboration — intend to produce a successful vaccine priced cheaply enough for widespread use in poor countries, in exchange for total start-up funding of $9.1 mn raised by the International AIDS Vaccine Initiative (IAVI). A small, US-based non-profit organization, the IAVI aims to expedite HIV vaccine testing in developing countries. Scientists consider the start-up funding sufficient to begin human testing in Kenya and South Africa within the next few years. The UK-Kenyan project, which joins researchers at Oxford University and the University of Nairobi, is developing a two-step vaccine using genetic matter extracted from the HIV virus and genetically engineered animal vaccinia virus. (A strain of vaccinia virus was used to eradicate smallpox.) The US-South African project links the University of North Carolina and AlphaVax, a small US-based biotechnology company, with the University of Cape Town. The vaccine being developed uses an altered strain of Venezuela equine encephalitis virus, a tropical microbe. In early lab and animal tests, both vaccines appear to successfully trigger the immune system to produce cells that hinder HIV infection. Because the HIV virus is highly variable, many consider the development of a viable vaccine to be a remote dream. Nevertheless, some 30 vaccines reportedly are at various stages of research and/or testing. |